- Healthcare technology company PKS (PKS) has placed its securities in a trading halt ahead of an upcoming capital raise
- The company has made no explicit indication of how much it is looking to raise or how it plans to spend the proceeds
- The trading halt is set to be lifted when a formal announcement is made regarding the raise on or before February 23
- PKS recently executed a $2.5 million renewal agreement with multinational conglomerate Philips for its RippleDown medical software
- Prior to the trading halt, PKS shares last traded at 37 cents each
Healthcare technology company PKS (PKS) has placed its securities in a trading halt ahead of an upcoming capital raise.
The company’s shares will remain in a trading halt until Tuesday, February 23 or until a formal disclosure regarding the raise.
PKS has made no explicit indication as to how much it is hoping to raise or how it plans to utilise the funds.
In terms of recent developments for the company, it executed a $2.5 million renewal agreement with multinational conglomerate Philips for PKS’ RippleDown software last month.
The software enables any pathologist or clinician to provide real-time clinical analysis, interpretations and treatment recommendations to patients by aggregating and analysing all available patient information.
The commercial terms of the agreement have also been altered from a fixed annual corporate licence fee and annual end-user fee to a per-episode fee.
Prior to the trading halt, PKS shares last traded at 37 cents each.